In summary, our results establish hepatic PTP4A1-mediated activation of the CREBH/FGF21 axis as a novel therapeutic strategy in NAFLD and hyperglycemia. Here, CREB3L3 is linked to metabolic dysfunction-associated steatotic liver disease.